{"id":"triptolide-containing-formulation","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL463763","moleculeType":"Small molecule","molecularWeight":"360.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Triptolide, a diterpenoid epoxide, has been shown to suppress the activity of NF-κB, a key transcription factor involved in the regulation of immune responses and inflammation. By inhibiting NF-κB, triptolide-containing formulations can reduce the production of pro-inflammatory cytokines and mediators, leading to anti-inflammatory and immunosuppressive effects. This mechanism of action is thought to contribute to the therapeutic efficacy of triptolide-containing formulations in various diseases.","oneSentence":"Triptolide-containing formulations exert their effects by inhibiting the transcription factor NF-κB, leading to anti-inflammatory and immunosuppressive effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:07.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT02115659","phase":"PHASE3","title":"Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2014-04","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Triptolide-Containing Formulation plus standard treatment."],"phase":"phase_3","status":"active","brandName":"Triptolide-Containing Formulation","genericName":"Triptolide-Containing Formulation","companyName":"Shanghai Changzheng Hospital","companyId":"shanghai-changzheng-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptolide-containing formulations exert their effects by inhibiting the transcription factor NF-κB, leading to anti-inflammatory and immunosuppressive effects. Used for Rheumatoid arthritis, Systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}